BRAF and non-small cell lung carcinoma: In the single-arm phase II TROPION-Lung05 trial, Dato-DXd was investigated as a treatment for patients with metastatic NSCLC and at least one or more genomic alterations, including EGFR, ALK, ROS proto oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), b-raf proto-oncogene (BRAF), rearranged during transfection (RET), or mesenchymal–epithelial transition factor (MET) exon 14 skipping, who received up to four prior lines of treatment, including at least one target therapy.